Cover Image

Cover Image

Fluorescence microscopy image of a peripheral blood smear from hagfish (Myxine glutinosa), the oldest surviving class of vertebrates, shows von Willebrand factor (VWF)–positive thrombocytes (red) surrounded by VWF-negative erythrocytes and spindle cells. The punctate pattern of staining suggests that hagfish VWF is stored in cytoplasmic granules. See the article by Grant et al on page 2548.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Von Willebrand factor: how unique structural adaptations support and coordinate its complex function

Advertisement intended for health care professionals

Table of Contents

INSIDE BLOOD COMMENTARIES

T-PLL: another check on the venetoclax list?
Clinical Trials & Observations

MCL-1 keeps a charming home for thymocytes

Marginal immunogenicity of factor VIII

PLENARY PAPER

Endogenous fibrinolysis facilitates clot retraction in vivo

PERSPECTIVE

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Clinical Trials & Observations

BLOOD SPOTLIGHT

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Clinical Trials & Observations

REVIEW ARTICLES

Myeloproliferative neoplasms: from origins to outcomes

When can we stop anticoagulation in patients with cancer-associated thrombosis?
Clinical Trials & Observations

HOW I TREAT

How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome

CLINICAL TRIALS AND OBSERVATIONS

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
Clinical Trials & Observations Brief Report

IMMUNOBIOLOGY AND IMMUNOTHERAPY

A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice

LYMPHOID NEOPLASIA

EBV latent membrane protein 2A orchestrates p27^kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice

PLATELETS AND THROMBOPOIESIS

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
Clinical Trials & Observations

RED CELLS, IRON, AND ERYTHROPOIESIS

The orphan nuclear receptor TR4 regulates erythroid cell proliferation and maturation

THROMBOSIS AND HEMOSTASIS

Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis

Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A

LETTER TO BLOOD

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Clinical Trials & Observations

BLOOD WORK

Unusual finding of a megakaryocyte in a peripheral blood smear

Signet-ring histiocytes in typhoid fever

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

T-PLL: another check on the venetoclax list? Clinical Trials & Observations

PLENARY PAPER

PERSPECTIVE

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Clinical Trials & Observations

BLOOD SPOTLIGHT

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML Clinical Trials & Observations

REVIEW ARTICLES

When can we stop anticoagulation in patients with cancer-associated thrombosis? Clinical Trials & Observations

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia Clinical Trials & Observations Brief Report

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study Clinical Trials & Observations

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

LETTER TO BLOOD

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights Clinical Trials & Observations

BLOOD WORK

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

T-PLL: another check on the venetoclax list?
Clinical Trials & Observations

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Clinical Trials & Observations

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Clinical Trials & Observations

When can we stop anticoagulation in patients with cancer-associated thrombosis?
Clinical Trials & Observations

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
Clinical Trials & Observations Brief Report

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
Clinical Trials & Observations

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Clinical Trials & Observations